Story
L-carnitine: the fat ferry you are rarely short of
Carnitine carries fatty acids into mitochondria to burn, but healthy people already have enough, oral carnitine barely reaches muscle, and weight-loss effects are tiny. Real shortfalls: genetic defects, long-term dialysis, some drug users.
Last updated
Overview and key questions
In short: Carnitine is the ferry that carries fatty acids into mitochondria to be burned, but at rest healthy people already have enough ferries, so most of the time carnitine is not what sets how fast fat burns. You may have heard “L-carnitine burns fat.” Fatty acids do need carnitine to enter mitochondria, but healthy people are not short of it and swallowed carnitine barely loads into muscle; pooled trials show only about a kilogram more weight lost, with no change in waist or body fat percentage.
Educational content, not medical advice. See a clinician about your own case.
Story path
Chapter 1
The ferry: how fatty acids get into mitochondria
What really sets the pace is a brake on the boarding step: when a molecule called malonyl-CoA builds up in the cell, fatty acids cannot board. In healthy people at rest, muscle holds far more empty ferries (free carnitine with no fatty acid attached) than can be used; mainly during high-intensity exercise might it fall short.
Most carnitine comes from meat and dairy; the rest is made by the liver, the kidneys and, in small amounts, the brain. The kidneys take back almost all the carnitine they filter out.
One common drug uses up carnitine: the epilepsy drug valproate can bind carnitine and carry it out in the urine. Anyone taking valproate who becomes more and more drowsy or hard to wake should get emergency care immediately.
Mechanism · The brake and the empty seats
The numbers show whether there are enough ferries. At rest, free carnitine in muscle is about 17 mmol/kg dry weight, roughly 5 mM; the boarding enzyme reaches half its top speed at only about 0.5 mM, about a tenfold gap. The authors of a review on muscle metabolism estimate that free carnitine has to drop to about 6 mmol/kg dry weight before it starts to slow boarding, and that this happens mainly during high-intensity submaximal exercise. This threshold is a hypothesis these authors derived from the data, not a ceiling that was measured directly.
So with empty ferries normally far more than enough, how hard this brake is pressed decides how fast fatty acids enter more than the number of ferries does.
Numbers · Where carriers come from and stay
Of the carnitine filtered by the kidneys, 98–99% is taken back into the blood by the renal tubules. Making it and recycling it means people who eat no meat are not short either: vegans and lacto-ovo vegetarians have normal carnitine levels. That is why carnitine counts as a conditionally essential nutrient: normally the body makes enough, and only in a few situations, such as premature birth or kidney dysfunction, does the need exceed what the body can make.
Chapter 2
Where swallowed carnitine goes
So far, the two ways that have loaded carnitine into healthy muscle both raised insulin at the same time: one is an infusion that lifts blood carnitine and insulin together; the other is taking carnitine with a large amount of carbohydrate twice a day for half a year. Whether insulin works by pushing OCTN2 harder is still a hypothesis.
The unabsorbed carnitine reaches the large intestine, where bacteria break down almost all of it. Part of it becomes trimethylamine (TMA), which the liver then turns into trimethylamine N-oxide (TMAO). Taking carnitine for a long time (two months or more) itself pushes gut bacteria to turn more of it into TMA. TMAO speeding up atherosclerosis has so far been seen only in mice; in people there is only an association.
Numbers · How much gets absorbed
The kidneys do not keep the extra that reaches the blood, either. Tubular reabsorption of carnitine has a threshold of about 40–60 μmol/L, close to the body's own blood level. So after extra carnitine is taken, the kidneys clear it faster and the surplus leaves in the urine. For example, if you stir a packet of carnitine powder into water before training, some of the brief surplus in your blood leaves through your urine this way.
Evidence · The trial that added carbohydrate
The volunteers were only male recreational athletes and the sample was small; they ate an extra 160 g of carbohydrate a day, about 600 kcal, and the researchers asked them to adjust their own diets to avoid gaining weight. Earlier studies that used infusions to raise blood carnitine and insulin at the same time lifted muscle total carnitine by only about 15%. In these experiments, fat oxidation at rest also seemed to rise after muscle carnitine went up, even though the empty ferries were already far more than enough, and the authors admit they do not know why.
So swallowing carnitine on its own barely loads it into healthy muscle; loading it costs a long-term intake of a lot of extra carbohydrate.
Chapter 3
Taking apart the carnitine weight-loss claim
Pooling dozens of , people taking carnitine lost a little over one kilogram more than controls on average, with no clear change in waist size or body fat percentage. Another pooled analysis found that the longer people took it, the smaller that gap became.
Say you drink a bottle of carnitine drink before the gym after work every day: even if you burn a little more fat for a while during the workout, that does not mean there will be less fat on your body. If fat loss is your only reason, there is no need to buy it.
Evidence · 37 trials pooled together
So at best, people lose about 1 kg more on average, and what they lose is not necessarily fat from the waist.
Evidence · The effect shrinks over time
So both pooled analyses found only a small gap of about 1 kg, and Pooyandjoo also found that the longer people took it, the smaller the gap became.
Chapter 4
Who is truly short: carnitine as a prescription
The other kind is acquired. Some drugs bind carnitine and carry it out in the urine, or block OCTN2 transport. In people on long-term hemodialysis, carnitine is steadily filtered out along with the dialysis.
All of these need a doctor's diagnosis: primary carnitine deficiency responds to oral carnitine, with treatment arranged by a doctor; whether to supplement for dialysis-related carnitine disorders is also a doctor's decision.
Clinical · Primary carnitine deficiency
Newborn screening can pick the disease up early. The disease responds to oral carnitine, with treatment arranged by a doctor. A person's genotype usually does not predict which metabolic or heart problems they will develop.
Red flag · Valproate and carnitine
Anyone taking valproate who becomes more and more drowsy, confused or hard to wake should get emergency care immediately. Do not stop the drug on your own, and do not start taking carnitine on your own; if you are worried about carnitine or ammonia, ask the doctor who prescribed it first.
Clinical · Dialysis and the kidneys
The US National Kidney Foundation held a consensus conference specifically on using L-carnitine for dialysis-related carnitine disorders. The authors state plainly that these recommendations are not guidelines or standards of care, but expert opinion to help doctors make decisions. So whether a person on dialysis should take carnitine is a judgment a kidney specialist makes for that person's situation.
Chapter 5
Acetyl-L-carnitine: the brain and nerve claims
In trials in Alzheimer's disease, no benefit was seen for cognition, severity of the disease, or daily function. For nerve pain caused by diabetes, pain fell only a little on average, and the certainty of the evidence is also very low. In a large trial aimed at preventing nerve damage from chemotherapy, the group taking ALCAR ended up with worse nerve damage later on.
Evidence · Alzheimer's disease
Another looked at mild cognitive impairment and mild Alzheimer's disease; pooling trials of 3 to 12 months gave a combined effect size of 0.20, a small effect. It merged many clinical and psychological measures into one score and did not discuss whether the effect matters clinically. The two analyses disagree, and the fact sheet from the US National Institutes of Health Office of Dietary Supplements sets them side by side and calls the effect still unclear.
So when an older relative's memory is slipping, the ALCAR trials do not agree: the Cochrane review saw no benefit, and another pooled analysis found only a small effect; memory that is clearly getting worse needs a doctor to look for the cause first.
Evidence · Diabetic nerve pain
Two of the studies were funded by an ALCAR manufacturer, and in the other two at least one author consulted for a manufacturer. The authors conclude that it is very uncertain whether ALCAR reduces pain over 6 to 12 months.
So for diabetic nerve pain, ALCAR at best lowers pain a little on average, and all 4 studies have ties to a manufacturer.
Safety · Worse during chemotherapy
The harm signal comes from a secondary end point, and from this one trial in one population. So in this trial, taking ALCAR during chemotherapy did not prevent nerve damage, and by week 24 it was worse.
References (14)
- Longo, N., Frigeni, M., & Pasquali, M. (2016). Carnitine transport and fatty acid oxidation. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1863(10), 2422–2435. 10.1016/j.bbamcr.2016.01.023
- Stephens, F. B., Constantin-Teodosiu, D., & Greenhaff, P. L. (2007). New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. The Journal of Physiology, 581(Pt 2), 431–444. 10.1113/jphysiol.2006.125799
- Evans, A. M., & Fornasini, G. (2003). Pharmacokinetics of L-carnitine. Clinical Pharmacokinetics, 42(11), 941–967. 10.2165/00003088-200342110-00002
- Lheureux, P. E., & Hantson, P. (2009). Carnitine in the treatment of valproic acid-induced toxicity. Clinical Toxicology, 47(2), 101–111. https://doi.org/10.1080/15563650902752376 10.1080/15563650902752376
- Wall, B. T., Stephens, F. B., Constantin-Teodosiu, D., Marimuthu, K., Macdonald, I. A., & Greenhaff, P. L. (2011). Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. The Journal of Physiology, 589(Pt 4), 963–973. 10.1113/jphysiol.2010.201343
- Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., et al. (2013). Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine, 19(5), 576-585. 10.1038/nm.3145
- Koeth, R. A., et al. (2019). L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. The Journal of Clinical Investigation, 129(1), 373–387. 10.1172/JCI94601
- Talenezhad, N., Mohammadi, M., Ramezani-Jolfaie, N., Mozaffari-Khosravi, H., & Salehi-Abargouei, A. (2020). Effects of l-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis. Clinical Nutrition ESPEN, 37, 9–23. https://doi.org/10.1016/j.clnesp.2020.03.008 10.1016/j.clnesp.2020.03.008
- Pooyandjoo, M., Nouhi, M., Shab-Bidar, S., Djafarian, K., & Olyaeemanesh, A. (2016). The effect of (L-)carnitine on weight loss in adults: A systematic review and meta-analysis of randomized controlled trials. Obesity Reviews, 17(10), 970–976. https://doi.org/10.1111/obr.12436 10.1111/obr.12436
- Jeukendrup, A. E., & Randell, R. (2011). Fat burners: nutrition supplements that increase fat metabolism. Obesity Reviews, 12(10), 841-851. 10.1111/j.1467-789X.2011.00908.x
- Eknoyan, G., Latos, D. L., & Lindberg, J. (2003). Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. American Journal of Kidney Diseases, 41(4), 868–876. https://doi.org/10.1016/s0272-6386(03)00110-0 10.1016/s0272-6386(03)00110-0
- Hudson, S., & Tabet, N. (2003). Acetyl-L-carnitine for dementia. Cochrane Database of Systematic Reviews, 2003(2), CD003158. https://doi.org/10.1002/14651858.CD003158 10.1002/14651858.CD003158
- Rolim, L. C., da Silva, E. M., Flumignan, R. L., Abreu, M. M., & Dib, S. A. (2019). Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews, 2019(6), CD011265. 10.1002/14651858.CD011265.pub2
- Hershman, D. L., Unger, J. M., Crew, K. D., Minasian, L. M., Awad, D., Moinpour, C. M., Hansen, L., Lew, D. L., Greenlee, H., Fehrenbacher, L., Wade, J. L., III, Wong, S. F., Hortobagyi, G. N., Meyskens, F. L., & Albain, K. S. (2013). Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. Journal of Clinical Oncology, 31(20), 2627-2633. 10.1200/JCO.2012.44.8738
Written from the sources listed above. Checked sentence by sentence against them in . No physician reviews this site: it explains how the body works, and it is not medical advice. How we make content
Spotted an error, or something unclear? Email us. We read every message, check it against the sources, and fix what's wrong.